Does dupixent help?

Does Dupixent help with chronic rhinosinusitis with nasal polyps?

Dupixent (dupilumab) reduces polyp size and improves nasal congestion in adults with chronic rhinosinusitis with nasal polyps who do not respond well to standard therapies. In two phase 3 trials, patients taking the drug showed a 34–42 % drop in polyp score and a 27–31 % improvement in nasal obstruction scores compared with placebo after 24 weeks. These benefits also extended to reduced need for oral steroids and fewer surgeries.

When does Dupixent patent protection expire?

The U.S. composition-of-matter patent for dupilumab expires in 2031, with possible pediatric extensions pushing final loss of exclusivity into 2032–2034. Biosimilar developers are already filing for approval, but regulatory data exclusivity currently blocks market entry before the patent period ends.

Why are companies challenging this patent?

Several biosimilar makers have filed inter partes review petitions at the Patent Trial and Appeal Board, arguing that the original claims covering dupilumab’s receptor-binding mechanism are anticipated or obvious. Regeneron and Sanofi are defending the patents, and the outcome will determine how soon lower-cost versions can reach patients.

How does Dupixent compare with other biologics for nasal polyps?

Unlike omalizumab or mepolizumab, which target IgE or IL-5 respectively, dupilumab blocks both IL-4 and IL-13 signaling. Head-to-head studies are limited, but indirect comparisons show larger polyp-size reductions and greater improvements in smell with dupilumab. Real-world data also suggest faster onset of symptom relief within four to eight weeks.

What side effects are patients asking about?

The most frequent reports involve injection-site reactions and conjunctivitis. In post-marketing surveillance, eye-related events occur in about 10 % of users, usually mild and treatable with topical therapy. Long-term safety data through five years show no new signals beyond those seen in trials.

Can patients switch from oral steroids to Dupixent?

Guidelines now recommend adding dupilumab for patients who rely on repeated courses of oral steroids. In practice, many clinicians taper steroids within the first month of dupilumab initiation, cutting cumulative steroid exposure by 70 % or more while maintaining symptom control.

Who makes Dupixent and how much does it cost?

Regeneron and Sanofi jointly market the drug. List price exceeds $3,800 per syringe; most insured patients pay $0–100 per month after copay assistance. Medicare Part D and Medicaid coverage varies by state formulary.

DrugPatentWatch.com